Novo Nordisk Aktie 461641 / US6701002056
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Trading-Depot | Watchlist |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Historisch | Analysen | |||||
Kurse + Charts + Realtime
News + Analysen
Fundamental
zugeh. Wertpapiere
|
23.11.2025 10:30:00
|
Novo Nordisk Just Took a Big Swing, Slashing Its GLP-1 Drug Prices. Will It Pay Off for the Healthcare Giant?
Over the past several years, GLP-1 agonist weight-loss drugs have evolved from a celebrity trend to arguably the hottest growth opportunity in the pharmaceutical industry.Novo Nordisk (NYSE: NVO) jumped out to an early lead with the immense popularity of its Ozempic and Wegovy (semaglutide), used to treat type 2 diabetes and obesity. However, a shortage in 2022 spurred competition from compounding pharmacies, and arch-rival Eli Lilly's (NYSE: LLY) Mounjaro and Zepbound (tirzepatide) have come on strong.Share prices of the Danish healthcare company have tumbled over the past 18 months, shedding two-thirds of their value. But after replacing its CEO earlier this year, Novo Nordisk is beginning to punch back in a big way.Continue readingWeiter zum vollständigen Artikel bei MotleyFool